Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Lophius Biosciences Appoints Dr. Robert Phelps as Director Business Operations

Published: Wednesday, December 04, 2013
Last Updated: Wednesday, December 04, 2013
Bookmark and Share
Dr. Phelps has longstanding experience in business development and licensing.

Lophius Biosciences GmbH has announced that Dr. Robert Phelps has joined the Company as Director Business Operations.

Dr. Phelps has more than thirteen years successful international experiences in business development and licensing in the biotech and pharma industry.

Lastly, he has been Head of Business Development & Licensing at SuppreMol GmbH in Munich, where he was responsible for all business development and licensing activities relating to the company’s clinical drug development candidates.

Previous to that, he has held business development and licensing positions at various biotechnology and pharmaceutical companies.

Dr. Phelps received his PhD in biochemistry from the University of Frankfurt and the Paul-Ehrlich-Institut in Germany, held a research position as a post-doctoral fellow at the Medical University of South Carolina, Charleston (SC), USA, and holds the Certified Licensing Professional (CLP) credentials.

"With his longstanding experience in business development and licensing, we are happy that we were able to get Robert on board" said Prof. Ralf Wagner, Managing Director of Lophius Biosciences. “He is a valuable addition to our team and will be instrumental in supporting our efforts to exploit the excellent development and marketing opportunities for our T cell-based diagnostic systems such as T-Track® CMV."

"I am very happy to join Lophius," Dr. Phelps added. "The Company has been highly successful in transforming their T cell monitoring platform technologies into viable products enabling doctors to individually adjust prophylactic and immunosuppressive therapy e.g. during solid organ and bone marrow transplantation to the benefit of patients. I am extremely impressed by the potential of their platform technologies and their deep product pipeline.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lophius Biosciences Closes Financing Round and Expands Management Board
Lophius Biosciences announces the closing of a further financing round with Prof. Dr Ralf Wagner been appointed as Managing Director.
Tuesday, January 22, 2013
Lophius Biosciences Achieves First Clinical Proof of Principle for T-Track® TB
Clinical proof of principle for detection of active tuberculosis and receives research funding.
Thursday, November 08, 2012
Lophius Biosciences Expands its Management Team and Prepares for Market Entry at the Beginning of 2012
The team is completed by Dr. Zanker from MedicalDevice+, an experienced expert in the field of regulatory affairs for diagnostic products.
Tuesday, July 12, 2011
Scientific News
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos